<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02664155</url>
  </required_header>
  <id_info>
    <org_study_id>1508189</org_study_id>
    <secondary_id>2016-000858-35</secondary_id>
    <nct_id>NCT02664155</nct_id>
  </id_info>
  <brief_title>Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants</brief_title>
  <acronym>VERDICT</acronym>
  <official_title>Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC)
      anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is
      associated with an increased risk of thromboembolic and bleeding complications compared to
      patients with normal renal function. Direct oral anticoagulants (DOAs) have been shown to be
      at least as effective and safe as SOC in VTE treatment. But in the clinical trials, moderate
      renally impaired patients were poorly represented and patients with severe renal
      insufficiency not at all. So no dose reduction was considered.

      Surprisingly, DOAs have been approved for VTE treatment in moderate and severe renally
      impaired patients. There is need to evaluate a reduced dose of DOAs for VTE treatment in
      patients with moderate and severe renal insufficiency.

      We plan to evaluate reduced doses of 2 DOAs (apixaban, rivaroxaban) compared to SOC in VTE
      patients with moderate or severe renal insufficiency in terms of net clinical benefit
      (recurrent VTE and major bleeding) at 3 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC)
      anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is
      associated with an increased risk of thromboembolic and bleeding complications compared to
      patients with normal renal function. These patients represent more than 20% of the VTE
      population in clinical practice. Direct oral anticoagulants (DOAs) have been shown to be at
      least as effective and safe as SOC in VTE treatment. But in the clinical trials, moderate
      renally impaired patients were poorly represented (&lt;10%) and patients with severe renal
      insufficiency not at all. So no dose reduction was considered.

      The new DOAs have also been developed for stroke prevention in atrial fibrillation (SPAF).
      Patients including in AF trials are generally older and more prone to present renal
      impairment (&gt;20%) than in VTE trials. So a reduced dose of DOAs was evaluated and shown to be
      at least as effective as, and safer than VKA in the subgroup of patients with moderate renal
      insufficiency (creatinine clearance between 30 to 50 ml/min).

      Surprisingly, DOAs have been approved for VTE treatment and SPAF in moderate and severe
      renally impaired patients (creatinine clearance between 15 to 30 mL/min). Moreover, patients
      have to receive a reduced dose of DOAs for SPAF but a full dose of DOAs for VTE that could be
      associated with an increased bleeding risk, as suggested by some subgroup analyses. So,
      there, there is need to evaluate a reduced dose of DOAs for VTE treatment in patients with
      moderate and severe renal insufficiency (creatinine clearance between 15 to 50 mL/min).

      Apixaban and rivaroxaban appear to be the best candidates since:

        -  both are approved in France in VTE patients

        -  they have mixed pathway of elimination (hepatic and renal)

        -  they have several other pharmacological similarities and they respective clinical trials
           have shown similar efficacy and safety profiles when compared with SOC for VTE
           treatment.

        -  they do not need to be preceded by initial parenteral heparins on the contrary to
           dabigatran and edoxaban. This allows evaluating the impact of DOAs in renally impaired
           patients independently from the initial heparins effect

        -  a reduced dose regimen is available and approved in AF

        -  the evaluation of 2 DAOs allows evaluating the concept of this new class in renally
           impaired VTE patients independently from the pharmaceutical companies.

      Finally we plan to evaluate reduced doses of 2 DOAs (apixaban, rivaroxaban) compared to SOC
      in VTE patients with moderate or severe renal insufficiency in terms of net clinical benefit
      (recurrent VTE and major bleeding) at 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non inferiority of reduced doses of DOAs</measure>
    <time_frame>Month 3</time_frame>
    <description>To demonstrate that reduced doses of DOAs (rivaroxaban or apixaban) are non-inferior to standard of care (heparins/VKA) on the net clinical benefit (recurrent VTE and major bleeding) in renally impaired patients suffering from an acute VTE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>Month 3</time_frame>
    <description>To demonstrate the non--inferiority of reduced dose of DOAs on the risk of major bleedings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Thromboembolism (VTE) events</measure>
    <time_frame>Month 3</time_frame>
    <description>To demonstrate the non--inferiority of reduced dose of DOAs on the risk of recurrent VTE.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>DOA : Direct Oral Anticoagulants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group receiving DOA regimens: patients will be secondarily randomly assigned within DOAs group between:
Apixaban (Eliquis速 tablet) 10 mg bid for 7 days then 2.5 mg bid for 3 months
Rivaroxaban (Xarelto速 tablet) 15 mg bid for 21 days then 15 mg od for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC : Standard Of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group receiving the standard of care (SOC), i.e. heparins/VKA regimen. Patients will receive the current recommended therapy: subcutaneous or intravenous UFH/VKA in case of severe renal insufficiency and subcutaneous LMWH/VKA in case of moderate renal insufficiency for at least 5 days. VKA will begin concomitantly and continue for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Direct Oral Anticoagulant</description>
    <arm_group_label>DOA : Direct Oral Anticoagulants</arm_group_label>
    <other_name>Eliquis速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Direct Oral Anticoagulant</description>
    <arm_group_label>DOA : Direct Oral Anticoagulants</arm_group_label>
    <other_name>Xarelto速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Standard Of Care</description>
    <arm_group_label>SOC : Standard Of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA</intervention_name>
    <description>Standard Of Care</description>
    <arm_group_label>SOC : Standard Of Care</arm_group_label>
    <other_name>vitamin K antagonists</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a moderate renal insufficiency defined by a creatinine clearance between
             30 to 50 ml/min (Cockcroft and Gault formulae) or a severe renal insufficiency
             (between 15 to 29 ml/min)

          -  Patients with acute objectively confirmed symptomatic proximal deep-vein thrombosis
             (DVT) or pulmonary embolism (PE) (with or without deep-vein thrombosis), planned to be
             treated for at least 3 months

          -  Patients &gt;18 years

          -  Life expectancy more than 3 months

          -  Social security affiliation

          -  Signed informed consent

        Exclusion Criteria:

          -  Indication for anticoagulants other than VTE

          -  Active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; a
             systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more
             than 110 mm Hg

          -  Anticoagulation for more than 72 hours prior to randomization

          -  Chronic liver disease or chronic hepatitis

          -  Patient at high risk of bleeding

          -  Creatinine clearance &lt;15 ml/min or end stage renal disease or indication for
             extra-renal dialysis

          -  Need for concomitant anti-platelet therapy other than aspirin 75-325 mg per day.
             However concomitant treatment with aspirin is discouraged in this population at
             bleeding risk.

          -  Concomitant use of a strong inhibitor of cytochrome P-450 3A4 (CYP3A4) (e.g., a
             protease inhibitor for human immunodeficiency virus infection or azole-antimycotics
             agents ketoconazole, itraconazole, voriconazole, posaconazole) or a CYP3A4 inducer
             (e.g., rifampin, carbamazepine, or phenytoin),

          -  Active pregnancy or expected pregnancy or no effective contraception

          -  Any contraindication listed in the local labeling of UFH, LMWH or VKA or oral
             anticoagulant.

          -  Cancer-associated VTE requiring long-term treatment with LMWH

          -  Life expectancy of less than 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MISMETTI Patrick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MISMETTI Patrick, MD</last_name>
    <phone>04 77 12 02 85</phone>
    <phone_ext>+33</phone_ext>
    <email>patrick.mismetti@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LABRUYERE Carine, CRA</last_name>
    <email>carine.labruyere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH ARRAS</name>
      <address>
        <city>Arras</city>
        <state>Boulevard Georges Besnier</state>
        <zip>62022</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandro AQUILANTI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sandro AQUILANTI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan GREBET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abed RIFAI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Tours</name>
      <address>
        <city>Tours</city>
        <state>H担pital Trousseau</state>
        <zip>37550</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis ANGOULVANT, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Denis ANGOULVANT, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe SAINT ETIENNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH d'Agen-N辿rac</name>
      <address>
        <city>Agen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albert TRINH-DUC, MD</last_name>
    </contact>
    <investigator>
      <last_name>Albert TRINH-DUC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Antoinette SEVESTRE-PIETRI, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Antoinette SEVESTRE-PIETRI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>Angers 9</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Marie ROY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre-Marie ROY, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas MOUMNEH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent AZZOLA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Besan巽on</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MENNEVEAU, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas MENNEVEAU, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno GENET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jo谷l CONSTANS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jo谷l CONSTANS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie SKOPINSKI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Cavale Blanche Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis COUTURAUD, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Francis COUTURAUD, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Norbert ANDRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nolwenn ASTRUC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aude BARNIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Am辿lie BAZIRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire DE MOREUIL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc DE SAINT-MARTIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aur辿lien DELLUC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique MOTTIER, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>C辿cile TROMEUR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle GOURVIL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe LEROYER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIA de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gw辿nol辿 ROHEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gw辿nol辿 ROHEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie RIVIERE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc DANGUY DES DESERTS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Castelnau-le-Lez</name>
      <address>
        <city>Castelnau Le Lez</city>
        <zip>34170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique BRISOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dominique BRISOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannot SCHMIDT, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jeannot SCHMIDT, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>G辿raldine GIROUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry MATHEVON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas DUBLANCHET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simone HEUSER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadine BREUIL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed HADJ-ABDELKADER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas FALVO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas FALVO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H担pital La Tronche Grenoble</name>
      <address>
        <city>Grenoble 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles PERNOD, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Gilles PERNOD, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H担pital Charles Foix - APHP Ivry sur Seine</name>
      <address>
        <city>Ivry sur Seine</city>
        <zip>94200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric PAUTAS, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Eric PAUTAS, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe LACROIX, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe LACROIX, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire GRANGE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claire GRANGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL - H担pital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H辿l竪ne DESMURS-CLAVEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>H辿l竪ne DESMURS-CLAVEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>C辿cile Audrey DUREL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magali AUBINEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Montpellier</name>
      <address>
        <city>Montpellier 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle QUERE, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle QUERE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique EL KOURI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dominique EL KOURI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emile FERRARI, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Emile FERRARI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HEGP - APHP Paris</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy MEYER, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Guy MEYER, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan MAREY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H担pital Louis Mourier- APHP Paris</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle MAHE, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle MAHE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline FOURGEAUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maxime DELRUE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ygal BENHAMOU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ygal BENHAMOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick MISMETTI, MD PhD</last_name>
      <phone>04 77 12 02 85</phone>
      <phone_ext>+33</phone_ext>
      <email>patrick.mismetti@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick MISMETTI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent BERTOLETTI, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine ACCASSAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie MOULIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>C辿cile DUVILLARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie DE MAGALHES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andr辿a BUCHMULLER-CORDIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique STEPHAN, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Dominique STEPHAN, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena-Mihaela CORDEANU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>S辿bastien GAERTNER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Marie FALLER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Toulon</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ELIAS, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Antoine ELIAS, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard COLIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-No谷l POGGI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie ELIAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIA de Toulon</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas PALEIRON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas PALEIRON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra BURA-RIVIERE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandra BURA-RIVIERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2016</study_first_submitted>
  <study_first_submitted_qc>January 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal insufficiency</keyword>
  <keyword>Direct oral anticoagulants (DOA)</keyword>
  <keyword>Deep Vein Thrombosis (DVT)</keyword>
  <keyword>Pulmonary Embolism (PE)</keyword>
  <keyword>Venous Thromboembolism (VTE)</keyword>
  <keyword>Heparins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

